CPT® Code 83913

Code deleted, see 81200-81479

Official Description

Molecular diagnostics; RNA stabilization

Common Language Description

Molecular diagnostics involve a series of tests designed to identify genetic mutations that may be linked to various medical conditions, including oncological (cancer-related), hematological (blood-related), neurological (nervous system-related), or other inherited disorders. These diagnostic studies are crucial for detecting carriers of specific genes or diseases, particularly in individuals who may not exhibit any symptoms but are at an increased risk or predisposed to developing certain conditions. Additionally, molecular diagnostics play a vital role in diagnosing and monitoring existing disease states, allowing for timely and appropriate medical interventions. A key component of these diagnostic procedures is RNA stabilization, which is essential for preserving the integrity of RNA prior to testing. RNA degradation can significantly impact the sensitivity of assays used for disease monitoring, potentially leading to inaccurate assessments and false results. To prevent RNA breakdown, one effective method involves placing fresh tissue samples in a stabilization solution that rapidly penetrates the tissue and inactivates nucleases, thereby protecting the RNA until nucleic acid isolation can be performed. This preservation technique allows samples to be stored in refrigeration for extended periods, ranging from weeks to months, without compromising the quality of the RNA, akin to the process of freezing samples in liquid nitrogen but with greater convenience. Another approach for stabilizing RNA involves the use of an RNA blood kit, which integrates the stabilization method during the blood collection and processing stages, ensuring that the RNA remains intact for subsequent analysis.

1. Indications

The procedure associated with CPT® Code 83913 is indicated for the following conditions:

Genetic Mutations Molecular diagnostic studies are performed to test for genetic mutations that may be associated with oncological, hematological, neurological, or other inherited disorders.
Carrier Detection This screening is utilized to identify carriers of specific genes or diseases, particularly in individuals who do not exhibit symptoms.
Risk Assessment The procedure is indicated for individuals at higher risk or predisposed to developing specific diseases, allowing for early intervention and monitoring.
Diagnosis and Monitoring Molecular diagnostics are essential for diagnosing and monitoring current disease states, providing critical information for treatment decisions.

2. Procedure

The procedure for RNA stabilization involves several key steps to ensure the integrity of RNA prior to testing:

Sample Collection Fresh tissue samples are collected and immediately placed in a stabilization solution. This solution is designed to quickly penetrate the tissue and inactivate nucleases, which are enzymes that can degrade RNA.
Preservation Once the samples are in the stabilization solution, they can be stored in refrigeration for an extended period, ranging from weeks to months. This preservation method maintains the quality of the RNA, preventing degradation until nucleic acid isolation is performed.
RNA Isolation After the appropriate storage period, the RNA is isolated from the stabilized samples for further analysis. This step is crucial for ensuring that the RNA remains intact and suitable for molecular diagnostic testing.
Blood Sample Stabilization In the case of peripheral blood samples, an RNA blood kit is utilized. This kit integrates the RNA stabilization method at the time of blood collection, ensuring that the RNA is preserved from the moment the sample is drawn.

3. Post-Procedure

Post-procedure care primarily involves the proper handling and storage of the stabilized samples until RNA isolation can be performed. It is essential to maintain the samples at the recommended refrigeration temperatures to ensure the integrity of the RNA. Once the RNA has been isolated, it can be subjected to various molecular diagnostic tests to detect genetic mutations or assess disease states. The results of these tests will guide further clinical decision-making and management of the patient’s condition.

Short Descr	MOLECULAR RNA STABILIZATION
Medium Descr	MOLECULAR DIAGNOSTICS RNA STABILIZATION
Long Descr	Molecular diagnostics; RNA stabilization
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Discontinued Code
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	none
MUE	Not applicable/unspecified.
CCS Clinical Classification	233 - Laboratory - Chemistry and Hematology